Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation.
Ashwinee Ragam, Anton M Kolomeyer, Jason S Kim, Natasha V Nayak, Christina Fang, Eliott Kim, David S Chu
文献索引:Eye Contact Lens 40(5) , 283-8, (2014)
全文:HTML全文
摘要
To evaluate the use of topical cyclosporine A (CsA) 1% emulsion in the treatment of chronic ocular surface inflammation (OSI).We conducted a retrospective chart review of patients with various forms of OSI treated with topical CsA 1% from 2001 to 2012.Twenty-nine patients (52 eyes) with various forms of OSI, including epidemic keratoconjunctivitis (n=14), chronic follicular conjunctivitis (n=12), Thygeson superficial punctate keratopathy (n=2), and vernal keratoconjunctivitis (n=1), were included. Twenty-seven patients had inflammation refractory to prior therapies. Twenty-four patients received concurrent medications with CsA 1%. Twenty-three of 24 patients on concurrent corticosteroids (CS) were able to taper their use while receiving CsA 1%. Thirteen patients experienced ocular discomfort with CsA 1%; one patient discontinued therapy all together as a result of these side effects; another switched to CsA 0.5% with improvement of adverse symptoms. Inflammation was controlled in 22 (92%) of the 24 patients who received CsA 1% for at least 2 months in duration.Topical CsA 1% helps to control inflammation and spares CS use in patients with chronic OSI.
相关化合物
相关文献:
2014-12-01
[Plast. Reconstr. Surg. 134(6) , 1213-23, (2014)]
2014-09-01
[Am. J. Physiol. Cell Physiol. 307(5) , C479-92, (2014)]
2014-09-01
[Arch. Toxicol. 88(9) , 1695-709, (2014)]
2014-01-01
[PLoS ONE 9(11) , e112413, (2014)]
2014-09-01
[Cell Biochem. Biophys. 70(1) , 367-81, (2014)]